Your trusted source

Drugmaker AstraZeneca announced on Monday that its experimental coronavirus vaccine has shown an average efficacy of 70% in its large scale trials -- the latest of several vaccine trials worldwide to post their results this month, CNN reported. 

The vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen -- when the vaccine was given as a half dose, followed by a full dose at least a month later -- and 62% efficacy in a second regimen -- when two full doses were given at least a month apart.

That averages to a 70% efficacy, AstraZeneca said.

The company said in a news release that its vaccine was "highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine."

UK Prime Minister Boris Johnson said it was "incredibly exciting news" and that while there were still safety checks to come, "these are fantastic results".